High-Throughput Sequencing Technology for Detection of Gene Mutations in Myeloid Malignancies and Its Clinical Prognostic Significance.
10.19746/j.cnki.issn.1009-2137.2023.04.010
- Author:
Min OUYANG
1
;
Bin JIANG
1
;
Mei-Xiang ZHANG
1
;
Wen-Qing HU
1
;
Lin SHI
1
;
Jian-Xin LIU
1
;
Ya-Yun ZHANG
1
;
Chun-Jian WANG
1
;
Fang WANG
1
;
Yao ZHANG
1
;
Han-Yun REN
2
Author Information
1. Department of Hematology, Peking University Intenational Hospital，Beijing 102206, China.
2. Department of Hematology, Peking University Intenational Hospital，Beijing 102206, China.E-mail: renhanyun@pkuih.edu.cn.
- Publication Type:Journal Article
- Keywords:
gene mutation;
high-throughput sequencing /next-generation sequencing;
myeloid malignancies;
prognosis
- MeSH:
Humans;
Leukemia, Myeloid, Acute/genetics*;
Nucleophosmin;
Prognosis;
Retrospective Studies;
High-Throughput Nucleotide Sequencing;
Myeloproliferative Disorders;
Mutation
- From:
Journal of Experimental Hematology
2023;31(4):992-998
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the gene mutations in patients with myeloid malignancies by high-throughput sequencing and explore the correlation between gene mutations and prognosis.
METHODS:A retrospective analysis was performed on 56 patients with myeloid malignancies who were hospitalized in the department of hematology, Peking University International Hospital from January 2020 to May 2021. The genetic mutations of the patients were detected by next-generation sequencing technology, and the correlation between the genetic mutations and prognosis of myeloid malignancies was analyzed.
RESULTS:In 56 patients, the number of mutated genes detected in a single patient is 0-9, with a median of 3. Sequencing results showed that the most common mutated genes were RUNX1(21.4%), TET2(17.9%), DNMT3A(17.9%), TP53(14.3%) and ASXL1(14.3%), among which the most common mutations occurred in the signaling pathway-related genes (23.3%) and the transcription factor genes (18.3%). 84% of the patients carried multiple mutated genes (≥2), and correlation analysis showed there were obvious co-occurring mutations between WT1 and FLT3, NPM1 and FLT3-ITD, and MYC and FLT3. TP53 mutation was more common in MDS patients.The overall survival time of patients with NRAS mutation was significantly shortened (P =0.049). The prognosis of patients with TP53 mutation was poor compared with those without TP53 mutation, but the difference wasn't statistically significant (P =0.08).
CONCLUSION:The application of next-generation sequencing technology is of great significance in myeloid malignancies, which is helpful to better understand the pathogenesis of the disease, to judge the prognosis and to find possible therapeutic targets.
